FDA Inspections All But Stopped In 2020 – But Quality-Related Warning Letters Kept On Coming
Executive Summary
The US agency sent 21 of the letters to device makers last year – the same number it mailed to firms in 2019.
You may also be interested in...
Inspection-Challenged FDA Defies Odds By Issuing Most Quality-Related Warning Letters Since 2017
US FDA data shared with Medtech Insight show that the number of quality-related warning letters sent to device manufacturers in calendar year 2021 ticked up 33% from 2020. Last year’s enforcement missives were also the most handed out by the agency in four years.
QA/RA Outlook 2021: 4 Hotspots To Watch, From ‘Hybrid’ US FDA Inspections To QSR Harmonization
Two QA/RA experts highlight hot-button topics that quality assurance and regulatory affairs professionals should keep an eye on in the medtech space this year.
On-Site Inspections Of US Device Makers Plummet 93% As FDA Scrambles For Virtual Solutions
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.